Premium
Aprotinin in the Management of Coagulopathy Associated with Amniotic Fluid Embolus
Author(s) -
Stroup Jeffrey S.,
Haraway G. Davin,
Beal J. Martin
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.5.689
Subject(s) - medicine , coagulopathy , amniotic fluid embolism , disseminated intravascular coagulation , complication , pregnancy , consumptive coagulopathy , fetal distress , coagulation disorder , surgery , obstetrics , intensive care medicine , anesthesia , coagulation , fetus , genetics , biology
Amniotic fluid embolus, also known as anaphylactoid syndrome of pregnancy is a rare complication of pregnancy. When it occurs, the maternal mortality rate may be as high as 86%, and in survivors, the morbidity rate may be just as high. Hallmark clinical features include maternal cardiovascular collapse with cyanosis, cardiopulmonary arrest, hypotension, hemorrhage associated with disseminated intravascular coagulation, and fetal distress. Management centers on strategies to improve oxygenation, support circulation, and correct the coagulopathy. We report the case of a patient who developed amniotic fluid embolus and was effectively managed with aprotinin to control the coagulopathy associated with this devastating complication of pregnancy.